Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer

Neel Shah, Ping Wang, John Wongvipat, Wouter R. Karthaus, Wassim Abida, Joshua Armenia, Shira Rockowitz, Yotam Drier, Bradley E. Bernstein, Henry W. Long, Matthew L. Freedman, Vivek K. Arora, Deyou Zheng, Charles L. Sawyers

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

In prostate cancer, resistance to the antiandrogen enzalutamide (Enz) can occur through bypass of androgen receptor (AR) blockade by the glucocorticoid receptor (GR). In contrast to fixed genomic alterations, here we show that GR-mediated antiandrogen resistance is adaptive and reversible due to regulation of GR expression by a tissue-specific enhancer. GR expression is silenced in prostate cancer by a combination of AR binding and EZH2-mediated repression at the GR locus, but is restored in advanced prostate cancers upon reversion of both repressive signals. Remarkably, BET bromodomain inhibition resensitizes drug-resistant tumors to Enz by selectively impairing the GR signaling axis via this enhancer. In addition to revealing an underlying molecular mechanism of GR-driven drug resistance, these data suggest that inhibitors of broadly active chromatin-readers could have utility in nuanced clinical contexts of acquired drug resistance with a more favorable therapeutic index.

Original languageEnglish (US)
Article numbere27861
JournaleLife
Volume6
DOIs
StatePublished - Sep 11 2017

Fingerprint

Androgen Antagonists
Glucocorticoid Receptors
Prostatic Neoplasms
Androgen Receptors
Drug Resistance
Pharmaceutical Preparations
Chromatin
Tumors
Tissue

ASJC Scopus subject areas

  • Neuroscience(all)
  • Medicine(all)
  • Immunology and Microbiology(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Shah, N., Wang, P., Wongvipat, J., Karthaus, W. R., Abida, W., Armenia, J., ... Sawyers, C. L. (2017). Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. eLife, 6, [e27861]. https://doi.org/10.7554/eLife.27861

Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. / Shah, Neel; Wang, Ping; Wongvipat, John; Karthaus, Wouter R.; Abida, Wassim; Armenia, Joshua; Rockowitz, Shira; Drier, Yotam; Bernstein, Bradley E.; Long, Henry W.; Freedman, Matthew L.; Arora, Vivek K.; Zheng, Deyou; Sawyers, Charles L.

In: eLife, Vol. 6, e27861, 11.09.2017.

Research output: Contribution to journalArticle

Shah, N, Wang, P, Wongvipat, J, Karthaus, WR, Abida, W, Armenia, J, Rockowitz, S, Drier, Y, Bernstein, BE, Long, HW, Freedman, ML, Arora, VK, Zheng, D & Sawyers, CL 2017, 'Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer', eLife, vol. 6, e27861. https://doi.org/10.7554/eLife.27861
Shah, Neel ; Wang, Ping ; Wongvipat, John ; Karthaus, Wouter R. ; Abida, Wassim ; Armenia, Joshua ; Rockowitz, Shira ; Drier, Yotam ; Bernstein, Bradley E. ; Long, Henry W. ; Freedman, Matthew L. ; Arora, Vivek K. ; Zheng, Deyou ; Sawyers, Charles L. / Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. In: eLife. 2017 ; Vol. 6.
@article{38fd4b402582482ba41905f2350733f2,
title = "Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer",
abstract = "In prostate cancer, resistance to the antiandrogen enzalutamide (Enz) can occur through bypass of androgen receptor (AR) blockade by the glucocorticoid receptor (GR). In contrast to fixed genomic alterations, here we show that GR-mediated antiandrogen resistance is adaptive and reversible due to regulation of GR expression by a tissue-specific enhancer. GR expression is silenced in prostate cancer by a combination of AR binding and EZH2-mediated repression at the GR locus, but is restored in advanced prostate cancers upon reversion of both repressive signals. Remarkably, BET bromodomain inhibition resensitizes drug-resistant tumors to Enz by selectively impairing the GR signaling axis via this enhancer. In addition to revealing an underlying molecular mechanism of GR-driven drug resistance, these data suggest that inhibitors of broadly active chromatin-readers could have utility in nuanced clinical contexts of acquired drug resistance with a more favorable therapeutic index.",
author = "Neel Shah and Ping Wang and John Wongvipat and Karthaus, {Wouter R.} and Wassim Abida and Joshua Armenia and Shira Rockowitz and Yotam Drier and Bernstein, {Bradley E.} and Long, {Henry W.} and Freedman, {Matthew L.} and Arora, {Vivek K.} and Deyou Zheng and Sawyers, {Charles L.}",
year = "2017",
month = "9",
day = "11",
doi = "10.7554/eLife.27861",
language = "English (US)",
volume = "6",
journal = "eLife",
issn = "2050-084X",
publisher = "eLife Sciences Publications",

}

TY - JOUR

T1 - Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer

AU - Shah, Neel

AU - Wang, Ping

AU - Wongvipat, John

AU - Karthaus, Wouter R.

AU - Abida, Wassim

AU - Armenia, Joshua

AU - Rockowitz, Shira

AU - Drier, Yotam

AU - Bernstein, Bradley E.

AU - Long, Henry W.

AU - Freedman, Matthew L.

AU - Arora, Vivek K.

AU - Zheng, Deyou

AU - Sawyers, Charles L.

PY - 2017/9/11

Y1 - 2017/9/11

N2 - In prostate cancer, resistance to the antiandrogen enzalutamide (Enz) can occur through bypass of androgen receptor (AR) blockade by the glucocorticoid receptor (GR). In contrast to fixed genomic alterations, here we show that GR-mediated antiandrogen resistance is adaptive and reversible due to regulation of GR expression by a tissue-specific enhancer. GR expression is silenced in prostate cancer by a combination of AR binding and EZH2-mediated repression at the GR locus, but is restored in advanced prostate cancers upon reversion of both repressive signals. Remarkably, BET bromodomain inhibition resensitizes drug-resistant tumors to Enz by selectively impairing the GR signaling axis via this enhancer. In addition to revealing an underlying molecular mechanism of GR-driven drug resistance, these data suggest that inhibitors of broadly active chromatin-readers could have utility in nuanced clinical contexts of acquired drug resistance with a more favorable therapeutic index.

AB - In prostate cancer, resistance to the antiandrogen enzalutamide (Enz) can occur through bypass of androgen receptor (AR) blockade by the glucocorticoid receptor (GR). In contrast to fixed genomic alterations, here we show that GR-mediated antiandrogen resistance is adaptive and reversible due to regulation of GR expression by a tissue-specific enhancer. GR expression is silenced in prostate cancer by a combination of AR binding and EZH2-mediated repression at the GR locus, but is restored in advanced prostate cancers upon reversion of both repressive signals. Remarkably, BET bromodomain inhibition resensitizes drug-resistant tumors to Enz by selectively impairing the GR signaling axis via this enhancer. In addition to revealing an underlying molecular mechanism of GR-driven drug resistance, these data suggest that inhibitors of broadly active chromatin-readers could have utility in nuanced clinical contexts of acquired drug resistance with a more favorable therapeutic index.

UR - http://www.scopus.com/inward/record.url?scp=85029428086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029428086&partnerID=8YFLogxK

U2 - 10.7554/eLife.27861

DO - 10.7554/eLife.27861

M3 - Article

C2 - 28891793

AN - SCOPUS:85029428086

VL - 6

JO - eLife

JF - eLife

SN - 2050-084X

M1 - e27861

ER -